Perceptive Advisors LLC bought $1.9M of ALDX
owner at Aldeyra Therapeutics, Inc.. 504,272 shares at an average of $3.84, traded Apr 1, 2024, filed Apr 3, 2024.
Score components
- +12Role10% owner
- +25Trade size$1.9M at market
- +3Relative to holdingsHoldings up 6%
- +8Price context72% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (2 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001062993-24-007959, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 1, 2024 | POpen-market purchase Common Stockindirect: See Footnote | +8,374 | $3.25 | $27k | 8,601,960 | Apr 3, 2024 |
| Apr 2, 2024 | POpen-market purchase Common Stockindirect: See Footnote | +186,051 | $3.44 | $640k | 8,788,011 | Apr 3, 2024 |
| Apr 3, 2024 | POpen-market purchase Common Stockindirect: See Footnote | +309,847 | $4.09 | $1.3M | 9,097,858 | Apr 3, 2024 |
Related signals
Other insiders at Aldeyra Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 52Moderate | ALDXbuy Aldeyra Therapeutics, Inc. | Todd C Brady President and CEO | $418k 250,000 shares | +17% | |
| 51Moderate | Aldeyra Therapeutics, Inc. | Richard Douglas director | $98k 70,000 shares | +56% | |
| 41Moderate | Aldeyra Therapeutics, Inc. | Michael Alfieri Principal Financial Officer | $7,100 5,000 shares | +200% | |
| 27Weak | ALDXbuy Aldeyra Therapeutics, Inc. | Michael Alfieri Principal Financial Officer | $13k 2,500 shares | - | |
| 25Weak | ALDXsell Aldeyra Therapeutics, Inc. | Stephen Machatha Chief Development Officer | $114k 22,073 shares | -9% | |
| 47Moderate | ALDXsell Aldeyra Therapeutics, Inc. | Perceptive Advisors LLC owner | $4.8M 3,400,000 shares | -37% | |
| 23Weak | ALDXbuy Aldeyra Therapeutics, Inc. | Nancy Miller-Rich director | $10k 922 shares | - | |
| 30Weak | Aldeyra Therapeutics, Inc. | Bruce Greenberg See Remarks | $51k 10,834 shares | -8% | |
| 31Weak | Aldeyra Therapeutics, Inc. | Stephen Machatha Chief Development Officer | $76k 16,041 shares | -6% | |
| 36Weak | Aldeyra Therapeutics, Inc. | Bruce Greenberg See Remarks | $45k 13,201 shares | -9% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.